In addition, there is little incen- uncertainties further reduce the attractiveness for investors.
tive to invest in the development of new antibacterials to Why are the returns low? Firstly (and rightly), new anti-
address future potential unmet needs that would increase bacterial medicines are reserved so as to preserve their
our preparedness to address AMR (figure 2c). These facts effectiveness in infections caused by resistant pathogens,
are increasingly recognized by stakeholders, including those thus limiting the volume of use. Secondly, the cost of antibac-
in government, public health and academia as well as the terials, even those for serious hospital infections, is low
industry. As stated in the recent report prepared by Eastern compared with many new medicines in other therapy areas.